| Lillehei, Kevin O |
SONOBIRD, NCT05902169: Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM |
|
|
| Recruiting | 3 | 560 | Europe, US | SonoCloud-9 (SC9), Carboplatin, CycloButane DiCarboxylic Acid (CBDCA), Lomustine, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU), Temozolomide, Temodal | CarThera | Glioblastoma, Recurrent Glioblastoma, GBM | 01/28 | 06/28 | | |
DCVax-L EAP, NCT02146066: Expanded Access Protocol for GBM Patients With Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221 |
|
|
| Available | N/A | | US | DCVax-L | Northwest Biotherapeutics | GBM, Glioblastoma Multiforme | | | | |
| Messersmith, Wells |
NCT03781154: Predictors of Physical Activity Maintenance in Colorectal Cancer Survivors |
|
|
| Completed | 3 | 31 | US | Group Exercise | University of Colorado, Denver, American Cancer Society, Inc., Colorado State University | Colorectal Cancer | 06/23 | 06/23 | | |
AGICC, NCT02723331: Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates |
|
|
| Active, not recruiting | 2 | 48 | US | Nab paclitaxel, Abraxane, Gemcitabine, Gemzar | Academic Thoracic Oncology Medical Investigators Consortium, Celgene Corporation, Criterium, Inc., University of Colorado, Denver | Pancreatic Cancer, Pancreatic Adenocarcinoma, Pancreas Ductal Adenocarcinoma | 12/22 | 05/25 | | |
| Active, not recruiting | 2 | 234 | Europe, US, RoW | Botensilimab, AGEN1181, Balstilimab, AGEN2034, Standard of Care | Agenus Inc. | Metastatic Colorectal Cancer | 02/25 | 07/25 | | |
NCT05167409: A Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer |
|
|
| Active, not recruiting | 2 | 48 | US | Evorpacept (ALX148), evorpacept, Cetuximab, Erbitux, Pembrolizumab, Keytruda | University of Colorado, Denver, ALX Oncology Inc., Merck Sharp & Dohme LLC, Eli Lilly and Company, Criterium, Inc., Academic GI Cancer Consortium (AGICC) | Microsatellite Stable Metastatic Colorectal Cancer | 12/25 | 03/26 | | |
NCT02521844: A Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumours |
|
|
| Active, not recruiting | 1 | 89 | US, RoW | ETC-1922159, Pembrolizumab | EDDC (Experimental Drug Development Centre), A*STAR Research Entities, PPD DEVELOPMENT, LP | Solid Tumors | 10/24 | 10/24 | | |
| Recruiting | 1 | 345 | Europe, US | NX-1607, Cbl-b Inhibitor, Paclitaxel | Nurix Therapeutics, Inc. | Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic or Unresectable Melanoma, Non-small Cell Lung Cancer (NSCLC), Metastatic Castration-resistant Prostate Cancer (mCRPC), Malignant Pleural Mesothelioma (MPM), Triple Negative Breast Cancer (TNBC), Metastatic Urothelial Carcinoma, Cervical Cancer, Diffuse Large B Cell Lymphoma (DLBCL), Richter Transformation, Microsatellite Stable Colorectal Carcinoma | 08/26 | 02/28 | | |
NCT02955446: Compassionate Use Protocol for PF-03084014 in Patients With Advanced Solid Tumor Malignancies |
|
|
| No Longer Available | N/A | | US | PF-03084014, Gamma Secretase Inhibitor | University of Colorado, Denver, SpringWorks Therapeutics, Inc. | Neoplasm, Desmoid Tumor | | | | |
| Berman, Brian |
NCT06771323: Safety and Effectiveness of Valbenazine as Adjunct Therapy to Botulinum Toxin Injections in Cervical Dystonia |
|
|
| Not yet recruiting | 2 | 20 | US | Valbenazine, Placebo | Virginia Commonwealth University, Neurocrine Biosciences | Cervical Dystonia | 01/26 | 01/26 | | |
NCT05157763: A Study to Evaluate the Safety and Efficacy of EscharEx (EX-02) in the Treatment of Basal Cell Carcinoma |
|
|
| Recruiting | 1/2 | 32 | US | EscharEx 5% (EX-02 formulation), EX-02 5% | MediWound Ltd | Superficial Basal Cell Carcinoma, Nodular Basal Cell Carcinoma | 05/22 | 06/22 | | |
CNXR-001D, NCT05279495: Double-Blind Study Determining the Efficacy of CannaXR in Decreasing UVA Premutagenic and Photoaging Markers |
|
|
| Completed | N/A | 20 | US | In a double-blinded fashion, 250 mg CANNAXR cream, TOPICAL CBD CANNAXR Cream, Topical VEHICLE cream | MINO Labs, LLC | Photoaging | 04/23 | 05/23 | | |
| Wang, Michael |
NCT03879135 / 2018-003453-16: A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willebrand Disease (VWD) |
|
|
| Active, not recruiting | 3 | 38 | Europe, US, RoW | rVWF, Vonvendi, Vonicog alfa, rFVIII, Octocog alfa, ADVATE | Baxalta now part of Shire, Takeda Development Center Americas, Inc. | Von Willebrand Disease (VWD) | 03/25 | 03/25 | | |
NCT02932618 / 2016-001477-33: A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD) |
|
|
| Recruiting | 3 | 34 | Europe, US, RoW | von Willebrand factor (Recombinant), VONVENDI, rVWF, BAX111, BAX 111, Antihemophilic Factor (Recombinant), ADVATE, Recombinant Factor VIII, rFVIII | Baxalta now part of Shire, Takeda Development Center Americas, Inc. | Von Willebrand Disease | 01/25 | 01/25 | | |
PRESent-6, NCT06568302: The Long-term Safety and Efficacy of SerpinPC in Subjects with Hemophilia Who Completed a Sponsored SerpinPC Clinical Trial |
|
|
| Recruiting | 3 | 150 | Europe, Canada, US, RoW | SerpinPC, Activated Protein C (APC) inhibitor | ApcinteX Ltd, Centessa Pharmaceuticals plc | Hemophilia a, Hemophilia B, Hemophilia a with Inhibitor, Hemophilia B with Inhibitor | 11/28 | 11/28 | | |
NCT06522386: GATE1: a Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients with Previously Untreated Mantle Cell Lymphoma |
|
|
| Recruiting | 2 | 40 | US | Pirtobrutinib, Rituximab, Rituxan, Venetoclax, ABT-199, GDC-0199 | M.D. Anderson Cancer Center | Mantle Cell Lymphoma | 02/27 | 02/29 | | |
| Active, not recruiting | 2 | 3 | Europe, US, RoW | SerpinPC, Activated Protein C (APC) inhibitor | ApcinteX Ltd, Centessa Pharmaceuticals plc | Hemophilia B with Inhibitor, Hemophilia B | 11/24 | 02/25 | | |
PRESent-2, NCT05789524: The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B |
|
|
| Active, not recruiting | 2 | 60 | Europe, Canada, US, RoW | SerpinPC, Activated Protein C (APC) inhibitor | ApcinteX Ltd, Centessa Pharmaceuticals plc | Hemophilia a, Hemophilia B | 11/24 | 02/25 | | |
V-MIND, NCT05910801: Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma |
|
|
| Recruiting | 2 | 100 | US | Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Lumbar Puncture, LP, Spinal Tap, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Tafasitamab, Immunoglobulin, Anti-(Human Cd19 Antigen) (Human-mus musculus Monoclonal MOR00208 Heavy Chain), Disulfide with Human-mus musculus Monoclonal MOR00208 .Kappa.-chain, Dimer, Monjuvi, MOR-00208, MOR00208, MOR208, Tafasitamab-cxix, XmAb5574, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto | Academic and Community Cancer Research United, National Cancer Institute (NCI) | Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | 12/29 | 12/30 | | |
NCT04014205: A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies |
|
|
| Active, not recruiting | 1/2 | 81 | Europe, US, RoW | Orelabrutinib (ICP-022) | Beijing InnoCare Pharma Tech Co., Ltd. | Part 1：r/r B-cell Malignancies, Part 2：B-cell Malignancies | 12/23 | 01/25 | | |
| Terminated | 1/2 | 9 | US | ONCT-808, Bridging Therapy | Oncternal Therapeutics, Inc | Relapsed/Refractory Aggressive B-Cell Malignancies | 09/24 | 09/24 | | |
| Completed | N/A | 65 | US | VIO Imaging | Enspectra Health, National Cancer Institute (NCI), National Institutes of Health (NIH) | Skin Condition, Skin Diseases, Skin Lesion, Skin Abnormalities, Skin Cancer | 08/23 | 08/23 | | |
NCT05940948: [Trial of device that is not approved or cleared by the U.S. FDA] |
|
|
| Withheld | N/A | 600 | NA | TruScore | [Redacted], Golden State Dermatology | Skin Cancer, Skin Melanoma, Skin Cancers - Squamous Cell Carcinoma, Skin Cancer, Non-Melanoma, Skin Cancers - Basal Cell Carcinoma, Skin Lesion | | | | |
| Active, not recruiting | N/A | 108 | US | | American Thrombosis and Hemostasis Network, Takeda | Von Willebrand Diseases | 12/24 | 01/25 | | |
| Recruiting | N/A | 750 | Canada | Cardiac monitoring device | Population Health Research Institute | Atrial Fibrillation, Atrial Flutter | 08/26 | 12/26 | | |
NCT05568459: A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standard of Care Factor IX Protein (FIX) Replacement Therapy |
|
|
| Recruiting | N/A | 120 | Europe, Canada, US | Non-Interventional | Regeneron Pharmaceuticals | Hemophilia B | 04/26 | 04/26 | | |
| Leehey, Maureen |
| Recruiting | N/A | 4500 | Europe, Canada, US, RoW | | Michael J. Fox Foundation for Parkinson's Research, Institute for Neurodegenerative Disorders | Parkinson Disease | 12/33 | 12/33 | | |
| Santoro, Nanette |
| Active, not recruiting | 4 | 720 | US | oral conjugated equine estrogens, transdermal estradiol, micronized progesterone, Placebo | University of Wisconsin, Madison, Kronos Longevity Research Institute, University of Utah, University of California, Albert Einstein College of Medicine of Yeshiva University, Brigham and Women's Hospital, Columbia University, Mayo Clinic, University of Washington, Yale University | Perimenopause, Coronary Disease, Estrogen Replacement Therapy, Hormone Replacement Therapy | 04/12 | 04/12 | | |
| Recruiting | 3 | 288 | US | Elagolix 200 MG, Orlissa, Placebo or SOC IVF | Yale University, University of Colorado, Denver, Northwestern University, University of North Carolina, Duke University, Johns Hopkins University | Infertility, Endometriosis | 06/26 | 06/26 | | |
NCT04173169: Pre-IVF Treatment With a GnRH Antagonist in Women With Endometriosis |
|
|
| Active, not recruiting | 3 | 112 | US | Elagolix 200 MG, Orlissa, Placebo or SOC IVF | Yale University, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), University of Colorado, Denver, Northwestern University, University of North Carolina | Infertility, Endometriosis | 05/25 | 05/25 | | |
NCT06686537: Convergent Mechanisms Underlying Reprometabolic Syndrome in Women |
|
|
| Not yet recruiting | 2 | 20 | US | Estradiol Patches | University of Colorado, Denver, Colorado Clinical & Translational Sciences Institute | Infertility, Female, Obesity | 10/26 | 12/26 | | |
NCT06414096: Use of Pulsatile Intravenous FSH to Mitigate Reprometabolic Syndrome |
|
|
| Recruiting | 1 | 5 | US | Follicle Stimulating Hormone, FSH | University of Colorado, Denver | Infertility, Obesity | 11/25 | 11/26 | | |
| Recruiting | N/A | 1000 | US | | Yale University, Johns Hopkins University, University of Texas at Austin, Penn State University, Northwestern University, The University of Texas Health Science Center at San Antonio, Wayne State University, Columbia University, University of Colorado, Denver, University of Oklahoma, University of Chicago, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Recurrent Pregnancy Loss | 12/26 | 12/26 | | |
| Campbell, Wayne W |
| Completed | N/A | 53 | US | Mediterranean Diet -- Mushrooms, Mediterranean Diet -- Control | Purdue University, Mushroom Council | Diet, Healthy | 11/22 | 11/22 | | |
| Completed | N/A | 7 | US | Yellow Oyster -- 84 g, Yellow Oyster -- 168 g, White button -- 84 g, White button -- 168 g, Control | Purdue University, Mushroom Council | Diet, Healthy | 05/21 | 05/21 | | |
NCT05559112: Effects of Vitamin D-Enriched Mushrooms on Vitamin D Status and Immune Function and Inflammatory Status in Adults |
|
|
| Completed | N/A | 36 | US | Vitamin D-enriched mushrooms, Study Powder | Purdue University | Vitamin D Deficiency | 04/24 | 04/24 | | |
NCT04820829: Effects of Proportioning Meat and Plant-based Protein-rich Foods on Cardiovascular Disease Risk Factors (S58) |
|
|
| Completed | N/A | 44 | US | High RM, low NSS, Moderate RM, Moderate NSS, Low RM, High NSS | Purdue University | Healthy Diet, Cardiovascular Risk Factor | 11/23 | 11/23 | | |
Mini-MED, NCT05500976: Metabolomics Initiative: Mediterranean-amplified vs Habitual Western Diet on Food Signatures, Health, and Microbiome |
|
|
| Active, not recruiting | N/A | 22 | US | Semi-controlled dietary intervention - Western, Semi-controlled dietary intervention - MiniMed | University of Colorado, Denver, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Cattlemen's Beef Association, Purdue University | Dietary Habits | 03/25 | 03/25 | | |
| Reisdorph, Nichole |
Mini-MED, NCT05500976: Metabolomics Initiative: Mediterranean-amplified vs Habitual Western Diet on Food Signatures, Health, and Microbiome |
|
|
| Active, not recruiting | N/A | 22 | US | Semi-controlled dietary intervention - Western, Semi-controlled dietary intervention - MiniMed | University of Colorado, Denver, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Cattlemen's Beef Association, Purdue University | Dietary Habits | 03/25 | 03/25 | | |
| Krebs, Nancy F |
| Recruiting | 3 | 4800 | RoW | IV iron infusion, Oral iron tablets | NICHD Global Network for Women's and Children's Health, Thomas Jefferson University, University of North Carolina, Chapel Hill, Kinshasa School of Public Health, University of Alabama at Birmingham, University Teaching Hospital, Lusaka, Zambia, University of Colorado, Denver, Institute of Nutrition of Central America and Panama, University of Virginia, International Centre for Diarrhoeal Disease Research, Bangladesh, Columbia University, Aga Khan University, Boston University, Lata Medical Research Foundation, Nagpur, Indiana University, Moi University, RTI International, Bill and Melinda Gates Foundation, KLE University Jawaharlal Nehru Medical College | Postpartum Anemia | 10/25 | 12/25 | | |
| Recruiting | N/A | 950000 | US, RoW | There is no intervention associated with the parent MNHR study. For the MNHR COVID sub-study, participants will be asked to provide a blood specimen at or near delivery. | NICHD Global Network for Women's and Children's Health | Pregnancy Outcome Trends in Low-resource Geographic Areas | 01/25 | 01/25 | | |
Mini-MED, NCT05500976: Metabolomics Initiative: Mediterranean-amplified vs Habitual Western Diet on Food Signatures, Health, and Microbiome |
|
|
| Active, not recruiting | N/A | 22 | US | Semi-controlled dietary intervention - Western, Semi-controlled dietary intervention - MiniMed | University of Colorado, Denver, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Cattlemen's Beef Association, Purdue University | Dietary Habits | 03/25 | 03/25 | | |
| Recruiting | N/A | 56 | RoW | Biofortified maize, Placebo | University of Colorado, Denver, Institute of Nutrition of Central America and Panama, Semilla Nueva | Zinc Absorption, Iron Absorption | 06/25 | 09/26 | | |
| Ginde, Adit A |
| Recruiting | 4 | 2364 | US | Ketamine, Etomidate | Vanderbilt University Medical Center, National Heart, Lung, and Blood Institute (NHLBI), Patient-Centered Outcomes Research Institute | Acute Respiratory Failure | 01/27 | 02/27 | | |
| Active, not recruiting | 3 | 6000 | US | Targeting Normoxemia (SpO2 90-96%; PaO2 60-100 mmHg) | University of Colorado, Denver, United States Department of Defense | Critical Illness, Wounds and Injury, Disease Attributes, Pathologic Processes | 11/22 | 02/25 | | |
| Active, not recruiting | 3 | 2000 | US | Targeting Normoxemia (SpO2 90-96%; PaO2 60-100 mmHg) | University of Colorado, Denver, United States Department of Defense | Critical Illness, Wounds and Injury, Disease Attributes, Pathologic Processes | 11/22 | 02/25 | | |
| Completed | 2/3 | 871 | US | TXA127, TRV027, Placebo, Fostamatinib | Sean Collins, National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI) | COVID-19, SARS-CoV-2 Infection, Coronavirus Infection | 10/23 | 12/23 | | |
NCT03789396: Pilot Study of Targeted Normoxia in Critically Ill Trauma Patients |
|
|
| Completed | N/A | 572 | US | Targeted Normoxia (oxygen saturation 90-96%), Usual Care Oxygenation | University of Colorado, Denver, United States Department of Defense | Trauma, Critical Illness, Oxygen Toxicity | 09/19 | 10/22 | | |
| Completed | N/A | 815 | Europe, US, RoW | | BioMérieux, Vanderbilt University Medical Center, Centre d'Investigation Clinique - Limoges | Infection, Sepsis | 05/22 | 05/22 | | |
| Completed | N/A | 1301 | US | Preoxygenation with Non-Invasive Positive Pressure Ventilation, Facemask Oxygen | Vanderbilt University Medical Center, University of Colorado, Denver | Acute Respiratory Failure | 10/23 | 11/23 | | |
| Recruiting | N/A | 417 | US | Massive Transfusion Group, Control Group | Brooke Army Medical Center, Congressionally Directed Medical Research Programs, The Metis Foundation, University of Colorado Health | Adverse Effects in the Therapeutic Use of Other and Unspecified Agents Affecting Blood Constituents | 07/27 | 09/27 | | |
| Kluger, Benzi |
NCT05274074: Social-Life Enhancing Activities for Caregivers |
|
|
| Completed | N/A | 61 | US | Social LEAF | University of Rochester, National Institute on Aging (NIA) | Social Connectedness | 07/23 | 07/23 | | |
| Recruiting | N/A | 710 | US | Parkinson Disease Standard Care, Online Community-Supported Palliative Care | University of Rochester, University of Colorado, Denver, Stanford University, Massachusetts General Hospital | Parkinson Disease Dementia, Parkinson Disease, Parkinson's Disease and Parkinsonism, Lewy Body Parkinsonism, Dementia With Lewy Bodies, Progressive Supranuclear Palsy, Corticobasal Degeneration, Multiple System Atrophy, Vascular Parkinsonism | 02/26 | 08/26 | | |
| Stevens-Lapsley, Jennifer |
NCT05900453: Novel Strategies for Personalized Clinical Decisions in Knee Arthroplasty |
|
|
| Completed | N/A | 675 | US | Clinical decision support (CDS) tool | University of Colorado, Denver, ATI Physical Therapy | Total Knee Replacement | 12/22 | 12/22 | | |
| Active, not recruiting | N/A | 138 | US | Control, Experimental: MOVE | University of Colorado, Denver, University of California, San Francisco, University of Delaware, National Institute on Aging (NIA) | Total Knee Arthroplasty, Older Adults | 12/24 | 12/24 | | |
NCT04942613: Engaging Medically Complex Veterans in Tele-Rehabilitation Using a Biobehavioral Approach |
|
|
| Completed | N/A | 50 | US | Motivational Interviewing Techniques, Physical Therapy Interventions, Education, Qualitative Interview | VA Office of Research and Development | Multimorbidity, Physical Deconditioning | 08/23 | 09/23 | | |
NCT06288438: Multicomponent Telerehabilitation to Engage Veterans in Effective Self-Management of Complex Health Conditions |
|
|
| Recruiting | N/A | 126 | US | Motivational Interviewing Techniques, Physical Therapy Interventions, Education, Health Status Updates, Physical Therapy Consult | VA Office of Research and Development | Multimorbidity, Physical Deconditioning | 11/26 | 03/28 | | |
NCT05492240: Advancing Rehabilitation Paradigms for Older Adults in Skilled Nursing Facilities |
|
|
| Recruiting | N/A | 2880 | US | i-STRONGER, Usual Care | University of Colorado, Denver, Aegis Therapies, Inc., National Institute on Aging (NIA) | Aging, Functional Recovery, Skilled Nursing Facility, Medically Complex, Deconditioning | 09/25 | 03/26 | | |
NCT05288803: Improving Rehabilitation for Veterans After Total Knee Arthroplasty Using Individualized Recovery Trajectories |
|
|
| Recruiting | N/A | 200 | US | Clinical decision support tool (CDS tool), Knee Recovery Tool | VA Office of Research and Development | Total Knee Arthroplasty | 03/25 | 03/26 | | |
| Wicklund, Matthew |
Fortify, NCT05775848: Study to Evaluate the Efficacy and Safety of BBP-418 (Ribitol) in Patients With Limb Girdle Muscular Dystrophy 2I (LGMD2I) |
|
|
| Active, not recruiting | 3 | 81 | Europe, US, RoW | BBP-418 (ribitol), Placebo | ML Bio Solutions, Inc. | Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I) | 07/27 | 07/27 | | |
NCT04886518: Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1 |
|
|
| Active, not recruiting | 2 | 30 | Canada, US | Pitolisant Oral Tablet, Placebo oral tablet | Harmony Biosciences, LLC | Myotonic Dystrophy 1, Excessive Daytime Sleepiness | 10/23 | 10/24 | | |
|
| Recruiting | N/A | 450 | Europe, Canada, US | | University of Kansas Medical Center, FSHD Society, Inc., Friends Research Institute, Inc., University of Rochester, University of Nevada, Reno, FSHD Canada, Avidity Biosciences, Inc., AMRA Medical, Seattle Children's Hospital, Dyne Therapeutics, Hoffmann-La Roche | FSHD | 12/26 | 01/27 | | |
| Recruiting | N/A | 80 | Europe, US, RoW | | Virginia Commonwealth University, Edgewise Therapeutics, Inc. | Becker Muscular Dystrophy, Muscular Dystrophies, Muscular Dystrophy in Children, Muscular Dystrophy, Becker | 05/25 | 05/26 | | |
| Active, not recruiting | N/A | 80 | Europe, US | | Virginia Commonwealth University, Newcastle University, Nationwide Children's Hospital, Washington University School of Medicine, University of Iowa, University of Minnesota, University of California, Irvine, Hugo W. Moser Research Institute at Kennedy Krieger, Inc., University of Colorado, Denver, University of Kansas Medical Center | Limb Girdle Muscular Dystrophy, Muscular Dystrophies | 06/25 | 06/25 | | |
| Active, not recruiting | N/A | 150 | US | | University of California, Irvine, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Sporadic Inclusion Body Myositis, Inclusion Body Myositis | 01/26 | 01/26 | | |
NCT03981575: Estab Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) |
|
|
| Recruiting | N/A | 700 | Europe, Canada, US, RoW | | Virginia Commonwealth University, University of Rochester, Stanford University, Ohio State University, University of Florida, University of Iowa, Ludwig-Maximilians - University of Munich, Fondazione Serena Onlus - Centro Clinico NeMO Milano, The Methodist Hospital Research Institute, Radboud University Medical Center, University College London Hospitals, University of California, Los Angeles | Myotonic Dystrophy 1, DM1 | 10/26 | 12/26 | | |
| Castorino, Kristin |
MKC-TI-193, NCT05904743: INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes |
|
|
| Completed | 4 | 141 | US | Afrezza, Technosphere Insulin, insulin degludec, Rapid-acting Insulin Analog, any FDA approved Rapid-acting Insulin Analog, Basal Insulin, any FDA approved Basal Insulin | Mannkind Corporation, Jaeb Center for Health Research | Diabetes Mellitus, Type 1 | 03/24 | 06/24 | | |
TRZ, NCT06009653: Effects of Tirzepatide Plus Intensive Lifestyle Therapy on Body Weight and Metabolic Health in Latinos With Obesity |
|
|
| Terminated | 4 | 32 | US | Standard Care, Culturally-tailored dietary and behavioral intensive lifestyle intervention, Placebo, Tirzepatide | Washington University School of Medicine, Eli Lilly and Company, National Institute on Minority Health and Health Disparities (NIMHD) | Obesity, Metabolic Disease | 05/24 | 05/24 | | |
QWINT-5, NCT05463744: A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy |
|
|
| Completed | 3 | 692 | Europe, Japan, US, RoW | Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec | Eli Lilly and Company | Type 1 Diabetes, Diabetes | 05/24 | 05/24 | | |
INHALE-GDM, NCT06535789: Inhaled Insulin vs Rapid-acting Injections for Post-meal Glucose Control in Women With Gestational Diabetes |
|
|
| Not yet recruiting | 2/3 | 30 | US | Inhaled Technosphere Insulin | Jaeb Center for Health Research, Mannkind Corporation | Diabetes, Gestational, Pregnancy Complications, Glucose Metabolism Disorders, Glucose Intolerance During Pregnancy | 12/24 | 12/24 | | |
NCT04905628: Performance of the Dexcom Continuous Glucose Monitoring (CGM) System in Pregnant Women With Diabetes Mellitus |
|
|
| Recruiting | N/A | 100 | US | Dexcom CGM System | DexCom, Inc. | Diabetes Mellitus | 03/22 | 04/22 | | |
| Active, not recruiting | N/A | 200 | Europe, US | Omnipod 5 System | Insulet Corporation | Type 1 Diabetes | 09/23 | 01/25 | | |
| Completed | N/A | 343 | US | Omnipod 5 Automated Glucose Control System | Insulet Corporation, Jaeb Center for Health Research | Type2 Diabetes | 03/24 | 03/24 | | |
NCT05714059: Safety and Effectiveness of the MiniMed™ 780G System With DS5 CGM |
|
|
| Completed | N/A | 250 | US | Insulin Pump with Continuous Glucose Monitoring | Medtronic Diabetes | Type 1 Diabetes | 12/23 | 12/23 | | |
NCT05238142: In-Home Study with MiniMed™ 780G Pump Automated Control in Type 2-Evaluation of the AHCL System in Adults with Insulin-requiring Type 2 Diabetes |
|
|
| Active, not recruiting | N/A | 575 | US | MiniMed™ 780G Insulin Pump system | Medtronic Diabetes | Type 2 Diabetes Treated with Insulin | 01/25 | 02/25 | | |
NCT06218147: Community-Based Nutrition-Lifestyle Therapy for Pregnant Latina Women With Diabetes |
|
|
| Recruiting | N/A | 30 | US | Nutrition-behavior lifestyle program, Plant forward dietary lifestyle intervention | Sansum Diabetes Research Institute | Diabetes Mellitus, Type 2, Diabetes Mel Gestational - in Pregnancy | 12/24 | 12/25 | | |
NCT04991142: Models of Nutrition From Continuous Glucose Monitors |
|
|
| Completed | N/A | 45 | US | | Texas A&M University, Sansum Diabetes Research Institute | Diabetes Mellitus, Type 2, Pre-diabetes, Diet Habit, Diet, Healthy | 08/24 | 08/24 | | |
| Not yet recruiting | N/A | 40 | US | Behavioral plant-based dietary intervention, Standard care | Washington University School of Medicine, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Sansum Diabetes Research Institute | Obesity, Metabolic Disease | 02/25 | 05/25 | | |
NCT06719531: SYNERGY PLUS: Evaluation of Next Generation Sensors (NGS) and Algorithm in Patients with Type 1 and Type 2 Diabetes |
|
|
| Not yet recruiting | N/A | 1500 | US | Continuous Glucose Monitoring | Medtronic Diabetes | Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus | 12/25 | 12/25 | | |
| Bennett, Jeffrey |
UNCOVER, NCT04753385: The RECOVER sUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes |
|
|
| Terminated | N/A | 138 | US | | LivaNova | Treatment Resistant Depression | 09/24 | 09/24 | | |
NCT06641271: Study to Investigate Vagus Nerve Stimulation Paired With Motor Task for Remyelination and Functional Recovery |
|
|
| Recruiting | N/A | 70 | US | Closed Loop Trans-Auricular Vagus Nerve Stimulation System, Placebo | University of Colorado, Denver | Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis | 11/27 | 11/27 | | |
RECOVER, NCT03887715: A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression |
|
|
| Recruiting | N/A | 6800 | US | Vagus Nerve Stimulation (VNS), VNS | LivaNova | Treatment Resistant Depression | 02/28 | 12/30 | | |
ACON, NCT05605951: Acute Optic Neuritis Network: an International Study That Invesitages Subjects With a First-ever Episode of Acute Inflammation of the Optic Nerve |
|
|
| Recruiting | N/A | 200 | Europe, Japan, US, RoW | non-interventional study | Experimental and Clinical Research Center, a cooperation between the Max Delbrück Center for Molecul | Demyelinating Diseases, Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder Attack, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Optic Neuritis | 12/25 | 12/25 | | |
| Lee, Joyce |
| Active, not recruiting | 3 | 202 | US | N-acetyl cysteine, NAC, Placebo | Weill Medical College of Cornell University, University of Virginia, University of Michigan, Pulmonary Fibrosis Foundation, University of Washington, National Heart, Lung, and Blood Institute (NHLBI), Three Lakes Foundation | Idiopathic Pulmonary Fibrosis | 02/26 | 02/26 | | |
BLISSc-ILD, NCT05878717: A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease |
|
|
| Recruiting | 2/3 | 300 | Europe, Japan, US, RoW | Belimumab, BENLYSTA™, GSK1550188, LymphoStat-B™, BENLYSTATM, GSK1550188, LymphoStat-B™, Placebo | GlaxoSmithKline | Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic | 07/27 | 07/27 | | |
|
NCT05671835: Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis |
|
|
| Recruiting | 2 | 75 | US | TTI-101, Placebo | Tvardi Therapeutics, Incorporated | Idiopathic Pulmonary Fibrosis | 03/25 | 07/25 | | |
MOUNTAIN, NCT06397677: Defining the Molecular and Radiologic Phenotype of Progressive RA Interstitial Lung Disease |
|
|
| Recruiting | N/A | 450 | US | Research Testing Performed (Laboratory), Information Collected as Standard of Care, Research Testing Performed | University of Colorado, Denver, National Heart, Lung, and Blood Institute (NHLBI), University of California, San Francisco, University of Michigan, University of Kansas | Rheumatoid Arthritis, Interstitial Lung Disease | 01/29 | 01/34 | | |
| Recruiting | N/A | 750 | US | | University of Colorado, Denver | Rheumatoid Arthritis, Interstitial Lung Disease | 06/27 | 06/27 | | |
| Monte, Andrew |
NCT06017622: Observational Study of THC Concentrations in Acute Cannabinoid Intoxication |
|
|
| Recruiting | N/A | 120 | US | | Anebulo Pharmaceuticals | Acute Cannabinoid Intoxication | 06/25 | 06/25 | | |
| Allen, Larry |
NCT04793880: Cost and Shared Decision-Making for Heart Failure |
|
|
| Completed | N/A | 247 | US | Medication Cost Information, Heart Failure Medicines Checklist | Emory University, Agency for Healthcare Research and Quality (AHRQ) | Chronic Heart Failure | 08/23 | 11/23 | | |
IICAPTAIN-HF, NCT06526988: Implementation and Interaction of Clinician And Patient-facing Tools Aiming to Intensify Neurohormonal Medicines for Heart Failure |
|
|
| Not yet recruiting | N/A | 2200 | US | EPIC-HF Patient-facing Tool, PROMPT-HF Clinician-facing Alert | University of Colorado, Denver, Patient-Centered Outcomes Research Institute, Yale University, Northwestern University, University of Utah, Sutter Health | Heart Failure With Reduced Ejection Fraction | 09/28 | 09/28 | | |
| Deane, Kevin |
| Recruiting | N/A | 750 | US | | University of Colorado, Denver | Rheumatoid Arthritis, Interstitial Lung Disease | 06/27 | 06/27 | | |
| Forman, Lisa |
NCT01846663: Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy |
|
|
| Terminated | 4 | 6 | US | Placebo, Rifaximin, XIFAXAN® Tablets | Bausch Health Americas, Inc. | Hepatic Encephalopathy | 02/16 | 02/16 | | |
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC) |
|
|
| Recruiting | 2 | 200 | Europe, Canada, US, RoW | Volixibat, SHP626, Placebo | Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc. | Primary Sclerosing Cholangitis | 09/25 | 12/25 | | |
NCT05569759: A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA) |
|
|
| Active, not recruiting | 2 | 24 | US | zetomipzomib, KZR-616, placebo, sterile water for injection, zetomipzomib in open-label extension | Kezar Life Sciences, Inc. | Autoimmune Hepatitis | 02/25 | 08/25 | | |
NCT06699121: A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC |
|
|
| Not yet recruiting | 2 | 87 | US | LB-P8 low-dose, LB-P8 high-dose, Placebo | LISCure Biosciences | Primary Sclerosing Cholangitis (PSC) | 03/28 | 02/29 | | |
| Reaven, Judy |
| Active, not recruiting | N/A | 73 | US | Facing Your Fears: ASD/ID, Cognitive behavioral therapy, Treatment as Usual | University of Colorado, Denver, United States Department of Defense | Autism Spectrum Disorder, Intellectual Disability, Anxiety, Emotion Regulation | 08/24 | 08/25 | | |
NCT05863520: A Comparison of Two School Based Interventions to Manage Anxiety in Autistic Students |
|
|
| Recruiting | N/A | 200 | US | Zones of Regulation, Facing Your Fears - School Based | University of Colorado, Denver, University of North Carolina, Chapel Hill, Emory University, Patient-Centered Outcomes Research Institute | Autism Spectrum Disorder, Anxiety Disorders, Emotion Regulation | 12/25 | 03/26 | | |
| Genuario, James |
| Terminated | N/A | 12500 | Europe, Canada, US, RoW | | Arthrex, Inc. | Degenerative and Traumatic Pathology of the Knee, Degenerative and Traumatic Pathology of the Shoulder and Elbow, Degenerative and Traumatic Pathology of the Foot and Ankle, Degenerative and Traumatic Pathology of the Hand and Wrist, Degenerative and Traumatic Pathology of the Hip | 07/23 | 07/23 | | |
NCT06320925: SportsPro: Post-Market Clinical Follow Up Study |
|
|
| Recruiting | N/A | 1500 | US | Standard of Care Treatment | Stryker Endoscopy | Shoulder Injuries, Knee Injuries, Hip Injuries | 06/24 | 12/24 | | |
